This website contains promotional content and is intended for Healthcare Professionals in the Republic of Ireland only. Adverse event reporting can be found at the bottom of the page
In this clinical summary you discover the real-world evidence of Toujeo® Insulin Glargine 300U/ml in people with T1 diabetes living in the UK. This was conducted in the SPARTA study - a descriptive, retrospective study.
Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.
Patient Materials
Find resources and support for your patients who have been prescribed Toujeo®. This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo®.
You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.
This site is intended for Healthcare Professionals in the Republic of Ireland and contains information on Sanofi Ireland medicine, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a Healthcare Professional in the Republic of Ireland. This site contains promotional information.
